Dexmedetomidine versus Dexamethasone as an adjuvant to 0.25% Ropivacaine in Ultrasound guided bilateral Rectus Sheath.
Phase 1
Not yet recruiting
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2024/01/062115
- Lead Sponsor
- Himalayan Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients aged between 18-60 years.
Physical status ASA I and ASA II
Undergoing elective midline abdominal laparotomy under General
Anesthesia
Exclusion Criteria
Patients aged less than 18 years or more than 60 years
Physical status ASA III and ASA IV
Allergic to any medication to be used in this study
Bleeding diathesis
Active skin infection over the area Of injection
Patients who shall not give consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the analgesic effects of Dexmedetomidine and Dexamethasone in rectus sheath blocks?
How does the efficacy of Dexmedetomidine compare to Dexamethasone as an adjuvant to Ropivacaine in post-laparotomy analgesia?
Are there specific biomarkers that predict patient response to adjuvant Dexmedetomidine or Dexamethasone in regional anesthesia?
What are the potential adverse events associated with combining Dexmedetomidine or Dexamethasone with Ropivacaine in rectus sheath blocks?
What are the current drug classes used as adjuvants in regional anesthesia for post-operative pain management in abdominal surgeries?